Learnings From Key Clinical Trials in Ovarian Cancer

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

Now Viewing

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

Video content is prompted by the following:

Lessons From Recent Clinical Trials

Key Discussion Points:

• Biomarker-Driven Treatment Selection
• Current challenge of selecting from multiple approved therapies with overlapping biomarkers

• Need for predictive power of biomarkers beyond simple positivity (eg, understanding implications of HER2 2+ vs folate medium expression)

• Sequencing implications of therapies with overlapping toxicity profiles
• Treatment Sequencing Considerations
• Critical importance of first therapy selection in platinum-resistant setting given patient drop-off with subsequent lines

• Limited understanding of how different biomarkers interact (BRCA, HRD, CCNE1, HER2, folate receptor)

• Patient-specific factors influencing treatment selection beyond biomarker status
• Evolution of Clinical Trial Design
• Moving away from “spray and pray” approaches with all-comers to biomarker-driven selection

• Learning from past experiences with immunotherapy trials that enrolled thousands without clear biomarker strategy

• Need for smarter trial designs that enable more precise patient selection

Notable Insights:

1. “Which one do I start with? Do I start with trastuzumab deruxtecan or do I start with mirvetuximab and bevacizumab?... Right now, we’re guessing.”
2. “We’ve said forever, ‘We don’t have mutations, and we don’t have anything to target.’ We have a lot of things to target. We just are at the early days of figuring out what it means.”
3. “3,000-plus patients exposed to 4 different sponsors’ frontline studies of immunotherapy and PARP...can’t do that again...I think we’ve learned that lesson, and we’re going to do better moving forward.”